Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer
May 11 2022 - 7:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical
company focused on novel and targeted oncology therapies, today
announced the appointment of Nora Brennan as Chief Financial
Officer effective May 25, 2022. Ms. Brennan has served on
Spectrum’s Board of Directors and as Chairperson of the Audit
Committee since December 2020, and will relinquish her Board duties
to assume this new role.
“We are thrilled to have Ms. Brennan join Spectrum’s senior
leadership team as we progress our two late-stage assets toward
commercialization,” stated Tom Riga, CEO of Spectrum
Pharmaceuticals. “Nora has been a strong board member and her
experience as the audit committee chair will serve her well in her
new role. She is an accomplished business executive and I’m looking
forward to working with her to advance our company.”
“Spectrum is in the midst of transformation with an exciting
future and I am looking forward to joining the management team.
During my time on the Board, I have experienced firsthand the great
potential in their clinical programs and confident in my ability to
help position the company to maximize shareholder value,” said Ms.
Brennan.
Most recently, Ms. Brennan served as Chief Financial Officer of
Fore Biotherapeutics, a private precision oncology company
pioneering the development of cancer therapies driven by functional
genomics. Prior to Fore, she was the Chief Financial Officer of
TELA Bio, Inc., where she guided the company through a successful
IPO and follow-on financing. Previously, Ms. Brennan spent 11 years
as the Senior Vice President of Treasury and Investor Relations at
Integra LifeSciences Holdings Corporation, where she served in
numerous capacities and led Integra through a myriad of financings.
She was key to the capital markets strategy over a significant
period of time and successfully integrated 18 acquisitions leading
to significant revenue growth for the company. She earned her B.A.
in Economics from the University of Illinois at Urbana-Champaign
and received her MBA from the University of Chicago Booth School of
Business.
With Ms. Brennan’s announcement, Brittany Bradrick, who was
recently appointed to the Board, will now assume the role of
Chairperson of the Audit Committee.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused
on acquiring, developing, and commercializing novel and targeted
oncology therapies. Spectrum has a strong track record of
successfully executing across the biopharmaceutical business model,
from in-licensing and acquiring differentiated drugs, clinically
developing novel assets, successfully gaining regulatory approvals
and commercializing in a competitive healthcare marketplace.
Spectrum has a late-stage pipeline with novel assets that serve
areas of unmet need. This pipeline has the potential to transform
the company in the near future. For additional information on
Spectrum Pharmaceuticals please visit www.sppirx.com.
Notice Regarding Forward-looking Statements
This press release may contain forward-looking statements
regarding future events and the future performance of Spectrum
Pharmaceuticals that involve risks and uncertainties that could
cause actual results to differ materially. These statements are
based on management's current beliefs and expectations. These
statements include, but are not limited to, statements that relate
to Spectrum’s business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical
and commercial products, the timing and results of FDA decisions,
and any statements that relate to the intent, belief, plans or
expectations of Spectrum or its management, or that are not a
statement of historical fact. Risks that could cause actual results
to differ include the possibility that Spectrum’s existing and new
drug candidates may not prove safe or effective, the possibility
that our existing and new applications to the FDA and other
regulatory agencies may not receive approval in a timely manner or
at all, the possibility that our existing and new drug candidates,
if approved, may not be more effective, safer or more cost
efficient than competing drugs, the possibility that our efforts to
acquire or in-license and develop additional drug candidates may
fail, our dependence on third parties for clinical trials,
manufacturing, distribution and quality control and other risks
that are described in further detail in the company's reports filed
with the Securities and Exchange Commission. The company does not
plan to update any such forward-looking statements and expressly
disclaims any duty to update the information contained in this
press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER
CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned
by Spectrum Pharmaceuticals, Inc. Any other trademarks are the
property of their respective owners.
© 2022 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220511005212/en/
Robert Uhl Managing Director, ICR Westwicke 858.356.5932
robert.uhl@westwicke.com
Tom Riga Chief Executive Officer 949.788.6700
InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024